Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation
Britta Höchsmann, … , Peter M. Krawitz, Taroh Kinoshita
Britta Höchsmann, … , Peter M. Krawitz, Taroh Kinoshita
Published August 20, 2019
Citation Information: J Clin Invest. 2019;129(12):5123-5136. https://doi.org/10.1172/JCI123501.
View: Text | PDF
Research Article Hematology Inflammation

Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation

  • Text
  • PDF
Abstract

Patients with paroxysmal nocturnal hemoglobinuria (PNH) have a clonal population of blood cells deficient in glycosylphosphatidylinositol-anchored (GPI-anchored) proteins, resulting from a mutation in the X-linked gene PIGA. Here we report on a set of patients in whom PNH results instead from biallelic mutation of PIGT on chromosome 20. These PIGT-PNH patients have clinically typical PNH, but they have in addition prominent autoinflammatory features, including recurrent attacks of aseptic meningitis. In all these patients we find a germ-line point mutation in one PIGT allele, whereas the other PIGT allele is removed by somatic deletion of a 20q region comprising maternally imprinted genes implicated in myeloproliferative syndromes. Unlike in PIGA-PNH cells, GPI is synthesized in PIGT-PNH cells and, since its attachment to proteins is blocked, free GPI is expressed on the cell surface. From studies of patients’ leukocytes and of PIGT-KO THP-1 cells we show that, through increased IL-1β secretion, activation of the lectin pathway of complement and generation of C5b-9 complexes, free GPI is the agent of autoinflammation. Eculizumab treatment abrogates not only intravascular hemolysis, but also autoinflammation. Thus, PIGT-PNH differs from PIGA-PNH both in the mechanism of clonal expansion and in clinical manifestations.

Authors

Britta Höchsmann, Yoshiko Murakami, Makiko Osato, Alexej Knaus, Michi Kawamoto, Norimitsu Inoue, Tetsuya Hirata, Shogo Murata, Markus Anliker, Thomas Eggermann, Marten Jäger, Ricarda Floettmann, Alexander Höllein, Sho Murase, Yasutaka Ueda, Jun-ichi Nishimura, Yuzuru Kanakura, Nobuo Kohara, Hubert Schrezenmeier, Peter M. Krawitz, Taroh Kinoshita

×

Figure 1

Clinical features of PIGT-PNH.

Options: View larger image (or click on image) Download as PowerPoint
Clinical features of PIGT-PNH.
(A) Schematics of normal and defective bi...
(A) Schematics of normal and defective biosynthesis of GPI-APs. (Top) In normal cells, GPI is synthesized in the ER from phosphatidylinositol (PI) by sequential reactions and assembled GPI is attached to proteins (orange oval). PIGA acts in the first step whereas PIGT acts in attachment of GPI to proteins. GPI-APs are transported to the plasma membrane (PM). (Middle) No GPI biosynthesis in PNH caused by PIGA defect. (Bottom) Accumulation of free GPI in PNH cells caused by PIGT defect. Non–protein-linked GPI is transported to the PM. (B) Time course of PNH clone sizes in patients G1, G3, and J1. Percentages of PNH cells in monocytes, granulocytes, erythrocytes, and reticulocytes are plotted as a function of time in days. Arrows, start of eculizumab therapy. (C) Examples of urticaria in G3 before the start of the anakinra treatment are shown on the left (chest) and middle (left upper leg); hemoglobinuria in G3 is shown on the right. Brightness was adjusted in the bottom chest image to more clearly show raised skin in the affected area. The pictures were made available by the patient. (D) Clinical courses of G3 in comparison to J1 (Figure 1 in ref. 8 was modified with additional data) including effective treatments. G3 (top) had meningitis 19 times between 62–65 years of age. Eculizumab therapy started at 66 years of age after a severe hemolysis. J1 (bottom) had meningitis 121 times between 53–69 years of age when eculizumab therapy started. Downward green arrows, onset of urticaria and/or arthralgia; blue middle height bars, meningitis; orange short bars, hemolysis; orange long bars, severe hemolysis; horizontal arrows of various lengths, treatment periods of effective therapies (anakinra and canakinumab were given with prednisolone); upward arrows with number and asterisk, serum samples taken for cytokine and other protein determination.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts